

Encise FY 2018 Snapshot

(NHI Price Based, Quick Data*)

(04/2018 to 03/2019)

Research Category

Annual

Date of Release

April 05, 2019




Monitoring Pharmaceutical Industry for the Society
MFPR Shibuya bldg., 2-5, Shibuya 1-chome, Shibuya-ku, Tokyo 150-0002
Phone : +81-3-6712-6339 | Fax : +81-3-6712-6343

* Please note that full year data for the FY 2018 (04/2018 to 03/2019) contains 'Quick Data' for the month of March 2019, while all the previous months' data is 'Fixed Data'. 'Quick Data' may slightly vary from the 'Fixed Data'.

Encise has prepared these reports by processing, editing, and developing estimates based on the ethical drug information we have collected. We do not guarantee the accuracy or completeness of this information, or that it meets any specific threshold in terms of content and/or quality.

Unless otherwise indicated, all of the content in the Report is owned by Encise, and Encise reserves all the rights including, but not limited to, copyrights contained or expressed in or relating to the Report, and they are protected by applicable laws. No one, except with and to the extent of the prior written consent of Encise, shall transfer the Report to any person or let any person use the Report, or quote, reproduce or copy any and all part of the Report.

FY 2018 (April 2018 to March 2019*)



Source: Encise Inc.

Monthly Sales	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
FY 2018 Monthly	886	804	773	804	810	720	881	828	892	796	767	803
% Growth MoM	10%	-9%	-4%	4%	1%	-11%	22%	-6%	8%	-11%	-4%	5%
FY 2018 Monthly Cumulative	886	1,690	2,463	3,268	4,078	4,798	5,679	6,507	7,399	8,195	8,962	9,765
FY 2017 Monthly	856	805	829	793	838	781	862	838	946	782	774	807
% Growth MoM	1%	-6%	3%	-4%	6%	-7%	10%	-3%	13%	-17%	-1%	4%
FY 2017 Monthly Cumulative	856	1,662	2,491	3,284	4,122	4,903	5,764	6,602	7,549	8,330	9,104	9,911


Source: Encise Inc.

* Please note that full year data for the FY 2018 (04/2018 to 03/2019) contains 'Quick Data' for the month of March 2019, while all the previous months' data is 'Fixed Data'. 'Quick Data' may slightly vary from the 'Fixed Data'.

Encise has prepared these reports by processing, editing, and developing estimates based on the ethical drug information we have collected. We do not guarantee the accuracy or completeness of this information, or that it meets any specific threshold in terms of content and/or quality.

Unless otherwise indicated, all of the content in the Report is owned by Encise, and Encise reserves all the rights including, but not limited to, copyrights contained or expressed in or relating to the Report, and they are protected by applicable laws. No one, except with and to the extent of the prior written consent of Encise, shall transfer the Report to any person or let any person use the Report, or quote, reproduce or copy any and all part of the Report.

Top 20 Brands (04/2018 to 03/2019*)



Source: Encise Inc.

Definitions:

** Total Sales of the Brand marketed by more than one company (including topical agents).


	Biologics – MAb and other large molecules whose structures cannot be drawn
	Small Molecule – molecular structure can be drawn on paper

* Please note that full year data for the FY 2018 (04/2018 to 03/2019) contains 'Quick Data' for the month of March 2019, while all the previous months' data is 'Fixed Data'. 'Quick Data' may slightly vary from the 'Fixed Data'.

Encise has prepared these reports by processing, editing, and developing estimates based on the ethical drug information we have collected. We do not guarantee the accuracy or completeness of this information, or that it meets any specific threshold in terms of content and/or quality.

Unless otherwise indicated, all of the content in the Report is owned by Encise, and Encise reserves all the rights including, but not limited to, copyrights contained or expressed in or relating to the Report, and they are protected by applicable laws. No one, except with and to the extent of the prior written consent of Encise, shall transfer the Report to any person or let any person use the Report, or quote, reproduce or copy any and all part of the Report.

Top 10 Therapeutic Classes (04/2018 to 03/2019*)




Source: Encise Inc.

* Please note that full year data for the FY 2018 (04/2018 to 03/2019) contains 'Quick Data' for the month of March 2019, while all the previous months' data is 'Fixed Data'. 'Quick Data' may slightly vary from the 'Fixed Data'.

Encise has prepared these reports by processing, editing, and developing estimates based on the ethical drug information we have collected. We do not guarantee the accuracy or completeness of this information, or that it meets any specific threshold in terms of content and/or quality.

Unless otherwise indicated, all of the content in the Report is owned by Encise, and Encise reserves all the rights including, but not limited to, copyrights contained or expressed in or relating to the Report, and they are protected by applicable laws. No one, except with and to the extent of the prior written consent of Encise, shall transfer the Report to any person or let any person use the Report, or quote, reproduce or copy any and all part of the Report.

Top 20 Companies (04/2018 to 03/2019*)



Source: Encise Inc.

Definitions:

** Sales by Marketing Authorization Holder

	Japanese Companies
	Foreign Companies

* Please note that full year data for the FY 2018 (04/2018 to 03/2019) contains 'Quick Data' for the month of March 2019, while all the previous months' data is 'Fixed Data'. 'Quick Data' may slightly vary from the 'Fixed Data'.

Encise has prepared these reports by processing, editing, and developing estimates based on the ethical drug information we have collected. We do not guarantee the accuracy or completeness of this information, or that it meets any specific threshold in terms of content and/or quality.

Unless otherwise indicated, all of the content in the Report is owned by Encise, and Encise reserves all the rights including, but not limited to, copyrights contained or expressed in or relating to the Report, and they are protected by applicable laws. No one, except with and to the extent of the prior written consent of Encise, shall transfer the Report to any person or let any person use the Report, or quote, reproduce or copy any and all part of the Report.

Encise | Research Center

Monitoring Pharmaceutical Industry for the Society

MFPR Shibuya bldg., 2-5, Shibuya 1-chome, Shibuya-ku, Tokyo 150-0002

Phone : +81-3-6712-6339 | Fax : +81-3-6712-6343